Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
详细信息 查看全文
- 作者：Marjet J.A.M. Braamskamp ; MDa ; b ; J.A.Braamskamp@amc.uva.nl" class="auth_mail" title="E-mail the corresponding author ; Gisle Langslet ; MDc ; glangsle@ous-hf.no" class="auth_mail" title="E-mail the corresponding author ; Brian W. McCrindle ; MD ; MPHd ; David Cassiman ; MD ; PhDe ; Gordon A. Francis ; MD ; FRCPCf ; Claude Gagné ; MD ; FLNA ; FAHAg ; Daniel Gaudet ; MD ; PhDh ; Katherine M. Morrison ; MD ; FRCPCi ; Albert Wiegman ; MD ; PhDb ; Traci Turner ; MDj ; D. Meeike Kusters ; MDa ; b ; Elinor Miller ; AB ; MDk ; Joel S. Raichlen ; MDk ; Jenny Wissmar ; MScl ; Paul D. Martin ; PhDm ; Evan A. Stein ; MD ; PhDj ; John J.P. Kastelein ; MD ; PhDa
- 关键词：Children ; Heterozygous familial hypercholesterolemia ; Low-density lipoprotein cholesterol ; Rosuvastatin ; Safety ; Tolerability
- 刊名：Journal of Clinical Lipidology
- 出版年：2015
- 出版时间：November-December 2015
- 年：2015
- 卷：9
- 期：6
- 页码：741-750
- 全文大小：492 K
文摘
- •
Heterozygous familial hypercholesterolemia can lead to premature cardiovascular disease.
- •
To prevent premature cardiovascular disease, statins should be initiated at an early age.
- •
CHARON evaluated efficacy and safety of rosuvastin in children aged 6 to 17 years.
- •
At 2 years, rosuvastatin 5–20 mg significantly reduced low-density lipoprotein cholesterol up to 45%.
- •
Treatment was well tolerated with no adverse effects on growth or sexual maturation.